Gray matter atrophy in patients with mild cognitive impairment/Alzheimer's disease over the course of developing delusions
Abstract
We conducted a neuroimaging analysis to understand the neuroanatomical correlates of gray matter loss in a group of mild cognitive impairment and early Alzheimer's disease patients who developed delusions.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 27, 2015
- Source ID
- 10.1002/gps.4291
Entities
People
- Colleen P. Millikin
- Corinne E. Fischer
- The Alzheimer Disease Neuroimaging Initiative
- Tom A. Schweizer
- Windsor Kwan‐chun Ting
- Zahinoor Ismail
Organizations
- Alzheimer's Association
- Alzheimer's Disease Neuroimaging Initiative
- Alzheimer's Drug Discovery Foundation
- BioClinica
- Canadian Institutes of Health Research
- Chiron Corporation
- Eli Lilly and Company
- GE HealthCare
- Hoffmann-La Roche
- Hotchkiss Brain Institute, University of Calgary
- Johnson & Johnson Pharmaceutical Research and Development
- Laboratoires Servier
- Medpace
- Merck & Co.
- Meso Scale Diagnostics (United States)
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Pfizer
- Roche (United States)
- St. Michael's Hospital
- Takeda Pharmaceutical Company
- United States Department of Defense
- University of Manitoba
- University of Toronto